Sentien Biotechnologies Names Dr. Allen R. Nissenson as Chief Medical Officer

LEXINGTON, Mass. (PRWEB) July 09, 2020 Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join Sentien’s executiv…

Source link

Related posts

Gene regulator may contribute to protein pileup in exfoliation glaucoma


Cardiac remodeling in response to embryonic crude oil exposure involves unconventional NKX family members and innate immunity genes [RESEARCH ARTICLE]


Escape responses of fish: a review of the diversity in motor control, kinematics and behaviour [REVIEW]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World